| Ytd | -4.44% | |
| 1y | -15.41% |
| Open | Prev Close | 5.16 | Low | High | Mkt Cap | 302.96M | |||
| Vol | 0.00 | Avg Vol | 241.11K | EPS | -1.16 | P/E | -4.45 | Forward P/E | -3.12 |
| Beta | 2.86 | Short Ratio | 7.62 | Inst. Own | 72.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 4.47 | 200-d Avg | 4.86 | 1yr Est | 12.00 |
FHTX News
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the anal
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new cl
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform a
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX)
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a
On Tuesday, 838 companies hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.